Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study...

por Van Cutsem, E., Valderrama, A., Bang, Y.-J., Fuchs, C.S., Shitara, K., Janjigian, Y.Y., Qin, S., Larson, T.G., Shankaran, V., Stein, S., Norquist, J.M., Kher, U., Shah, S., Alsina, M.
Publicado 2021